News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 109–144
- Matches
- 1030
- Sources here
- 24
- Companies here
- 11
Active search
1030 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Form 8K Shattuck Labs Inc For: 11 August By Investing.com
This article announces that Shattuck Labs Inc. filed a Form 8K on August 11, according to Investing.com. The brief news item includes the company's stock symbol STTK and its positive performance for the day. No further details about the content of the Form 8K …
Wasatch Advisors LP Purchases 692,735 Shares of Pattern Group Inc. $PTRN
Wasatch Advisors LP increased its stake in Pattern Group Inc. by 28.4% in the second quarter, acquiring an additional 692,735 shares to now own 3.14 million shares valued at $79.0 million. Pattern Group reported better-than-expected quarterly earnings of $0.15 EPS on $876.77 million in …
Manhattan Associates CEO Eric Clark sells $593k in company stock
Manhattan Associates CEO Eric Clark sold 3,000 shares of company stock for $593,280. This sale comes as the company reports strong Q2 2026 results with increased earnings and revenue, leading to positive analyst ratings and raised price targets from Truist Securities and Stifel. Despite …
Companies & Markets Analysis 12/08/2026: Hill & Smith, ECO Animal Health, Titon Holdings, CLS Holdings, Balfour Beatty, 80 Mile, Atalaya Mining Copper SA, Evoke, Seeing Machines, Kazera Global, Savannah Resources, Alternative Income REIT, Predator
Mattel, Inc. (NASDAQ:MAT) Given Average Recommendation of "Hold" by Brokerages
Fourteen research firms have given Mattel, Inc. (NASDAQ:MAT) a consensus "Hold" rating, with an average 1-year target price of $17.33. The company's stock opened at $15.03 and institutional investors own 97.15% of its shares. Mattel reported a 10.5% increase in revenue year-over-year to $1.13 …
Matthews International Corporat (MATW) Stock forecasts
Argus has lowered the target price for Matthews International Corp (MATW) to $24.00, while the current price stands at $23.25. The company, which operates in personal services, provides brand solution services, memorialization products, and industrial products across the United States and Europe. The report, …
Brand Investments and Cost Efforts to Stoke Profit Margin Expansion at Mattel in 2027 and Beyond
Mattel anticipates profit margin expansion in 2027 and beyond, following a soft outlook for 2026 that includes sales growth of 3%-6% and an operating margin between 10.5%-11.4%. Despite a current $225 million cost-saving program, the company expects a second year of margin contraction. However, …
Lattice Semiconductor (LSCC) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 2:00 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Rick Muscha Chief Executive Officer - Fouad Tamer Executive Vice President and Chief Financial Officer - Lorenzo A. Flores Chief Executive Officer …
Manhattan Associates Insider Sold Shares Worth $593,280, According to a Recent SEC Filing
An insider at Manhattan Associates (MANH) recently sold shares valued at $593,280, as detailed in a new SEC filing. This transaction follows another insider sale on July 31st worth over $1 million. The article also provides recent company news, including strong Q2 2026 earnings …
Transcript : Lattice Semiconductor Corporation Presents at The KeyBanc Technology Leadership Forum 2026, Aug-11-2026 01
This article is a transcript from the KeyBanc Technology Leadership Forum 2026, where John Vinh from KeyBanc Capital Markets introduced Lattice Semiconductor Corporation. The full content of the presentation is restricted to subscribers. The article also lists recent news and financial data related to …
Shattuck Labs, Inc. Stock 12‑Month Price Target Cut to $14.86, Implies 108% Upside
Analysts have lowered the average 12-month price target for Shattuck Labs, Inc. (STTK) stock from $15 to $14.86, implying a potential upside of 108% based on the August 10 closing price. Despite the reduction, the consensus rating from 9 covering analysts remains a "Buy," …
STTK Maintained by HC Wainwright & Co. -- Price Target Lowered to $14
HC Wainwright & Co. has maintained a 'Buy' rating for Shattuck Labs (STTK) but lowered its price target from $18.00 to $14.00, reflecting a cautious outlook due to the company's significant overvaluation, low profitability, and mixed insider sentiment. Despite developing innovative therapies, the stock …
HC Wainwright Cuts Shattuck Labs (NASDAQ:STTK) Price Target to $14.00
HC Wainwright has reduced its price target for Shattuck Labs (NASDAQ:STTK) to $14.00 from $18.00, while maintaining a "buy" rating, indicating a potential upside of approximately 94%. Despite the lowered target, analysts collectively give the company a "Moderate Buy" rating with an average target …
Shattuck Labs 2Q Loss/Shr 12c >STTK
Shattuck Labs (STTK) reported a second-quarter loss per share of 12 cents. Further details regarding their financial performance were not provided in this brief announcement.
Signet Jewelers Selects Mattel Exec to Lead Zales, Banter
Signet Jewelers has appointed Jamie Cygielman, a veteran consumer brands executive from Mattel, as the new president of Zales and Banter, effective August 24. Cygielman will lead the brands' growth strategies, focusing on innovation and customer experiences. This appointment follows the recent addition of …
Manhattan Associates (MANH) CEO Eric Clark plans sale of 3,000 common shares
Manhattan Associates CEO Eric Clark has filed to sell 3,000 shares of common stock through UBS Financial Services Inc, with an aggregate market value of $592,962.53. The filing also details a prior grant of 8,666 shares to Clark on February 14, 2025, and a …
Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases
Shattuck Labs has released an investor deck detailing its strategy to develop DR3-blocking antibodies, primarily SL-325, for inflammatory and immune-mediated diseases. A Phase 2b trial for SL-325 in Crohn's disease is set to begin in Q3 2026, with initial data expected in 1H 2028. …